Inmed pharmaceuticals announces commencement of phase 2 clinical trial investigating cannabinol (cbn), a rare cannabinoid, in the treatment of epidermolysis bullosa

Vancouver, british columbia, sept. 30, 2021 (globe newswire) -- inmed pharmaceuticals inc. (“inmed” or the “company”) (nasdaq: inm), a leader in the manufacturing and clinical development of rare cannabinoids, today announced that it has commenced its phase 2 clinical trial of inm-755 (cannabinol) cream in the treatment of epidermolysis bullosa (“eb”). this marks the first time cannabinol has advanced to a phase 2 clinical trial to be studied as a therapeutic option to treat a disease.
INM Ratings Summary
INM Quant Ranking